Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
Ruth Harvey, Giada Mattiuzzo

, Mark Hassall, Andrea Sieberg, Marcel A. Müller, Christian Drosten, Peter Rigsby, Christopher J. Oxenford, and study participants
Author affiliations: National Institute for Biological Standards and Control—MHRA, Potters Bar, UK (R. Harvey, G. Mattiuzzo, M. Hassall, P. Rigsby); Charité-Universitätsmedizin Berlin, Berlin, Germany (A. Sieberg, M.A. Müller, C. Drosten); German Centre for Infection Research, Berlin (M.A. Müller, C. Drosten); World Health Organization, Lyon, France (C.J. Oxenford).
Main Article
Table 4
GCV percentage (%GCV) for 5 individual serum samples in study of serologic assays for Middle East respiratory syndrome coronavirus*
Sample no. |
% GCV
|
Endpoint |
Potencies vs. sample 4 |
Potencies vs. sample 16 |
1 |
414 |
237 |
342 |
5 |
405 |
173 |
70 |
9 |
555 |
89 |
69 |
11 |
682 |
50 |
73 |
12 |
816 |
138 |
43 |
Main Article
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.